TRENDY Follow-up: Study on Endothelial Function in Subjects With Type 2 Diabetes Mellitus
NCT ID: NCT00905528
Last Updated: 2015-03-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
69 participants
OBSERVATIONAL
2002-01-31
2004-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Nitric Oxide (NO) Activity and Diabetic Nephropathy
NCT00136188
Diabetic Patients With End-Stage Renal Disease
NCT00435786
Nephropathy In Type 2 Diabetes and Cardio-renal Events
NCT00535925
Effect of Angiotensin Converting Enzyme Inhibitor, Lisinopril, on Renal Blood Flow and Its Correlation With Proteinuria Reduction in Subjects With Type 2 Diabetes and Kidney Disease
NCT01101269
PeRsOnalising Treatment Of Diabetic Nephropathy:
NCT03509454
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Subjects with type 2 diabetes mellitus, eGFR \> 80, hypertension, no overt proteinuria
Telmisartan 80 mg/d
B
Subjects with type 2 diabetes mellitus, eGFR \> 80, hypertension, no overt proteinuria
Ramipril 10 mg/d
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Telmisartan 80 mg/d
Ramipril 10 mg/d
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Symptomatic cardiovascular disease
30 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Erlangen-Nürnberg Medical School
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Roland E Schmieder, Prof.
Role: PRINCIPAL_INVESTIGATOR
Clinical Research Center, Department of Nephrology and Hypertension, University of Erlangen-Nuremberg
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Erlangen-Nuremberg
Erlangen, Bavaria, Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ritt M, Ott C, Delles C, Schneider MP, Schmieder RE. Impact of the endothelial nitric oxide synthase gene G894T polymorphism on renal endothelial function in patients with type 2 diabetes. Pharmacogenet Genomics. 2008 Aug;18(8):699-707. doi: 10.1097/FPC.0b013e32830500b1.
Ritt M, Ott C, Raff U, Schneider MP, Schuster I, Hilgers KF, Schlaich MP, Schmieder RE. Renal vascular endothelial function in hypertensive patients with type 2 diabetes mellitus. Am J Kidney Dis. 2009 Feb;53(2):281-9. doi: 10.1053/j.ajkd.2008.10.041. Epub 2008 Dec 19.
Natale P, Palmer SC, Navaneethan SD, Craig JC, Strippoli GF. Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2024 Apr 29;4(4):CD006257. doi: 10.1002/14651858.CD006257.pub2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SFB TP B5
Identifier Type: -
Identifier Source: secondary_id
Re.-No. 3204
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.